Drug regulators cited Novartis for "significant violations" of manufacturing regulations at its three generic drug plants in the U.S. and Canada, several of which were repeat offenses.
FDA cites violations at three Novartis plants
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Recommended for You